Agreement of reported vascular access on the medical evidence report and on medicare claims at hemodialysis initiation

BMC Nephrology

Areef Ishani³  Robert N Foley⁴  Arman Faravardeh¹  Shu-Cheng Chen²  James P Ebben²  Allan J Collins⁴  Craig A Solid² 

[1] Division of Renal Diseases and Hypertension, University of Minnesota, Minneapolis, Minnesota USA;United States Renal Data System, Minneapolis Medical Research Foundation, 914 South 8th Street, Suite S4.100, Minneapolis, Minnesota 55404, USA;Section of Nephrology, Minneapolis VA Health Care System, Minneapolis, Minnesota USA;Department of Medicine, University of Minnesota, Minneapolis, Minnesota USA

关键词: Vascular access;    Validation;    Medicare;    Hemodialysis;   

Others  :  1082729
DOI  :  10.1186/1471-2369-15-30

 received in 2013-05-23, accepted in 2014-02-02,  发布年份 2014

【 摘 要 】

Background

The choice of vascular access type is an important aspect of care for incident hemodialysis patients. However, data from the Centers for Medicare & Medicaid Services (CMS) Medical Evidence Report (form CMS-2728) identifying the first access for incident patients have not previously been validated. Medicare began requiring that vascular access type be reported on claims in July 2010. We aimed to determine the agreement between the reported vascular access at initiation from form CMS-2728 and from Medicare claims.

Methods

This retrospective study used a cohort of 9777 patients who initiated dialysis in the latter half of 2010 and were eligible for Medicare at the start of renal replacement therapy to compare the vascular access type reported on form CMS-2728 with the type reported on Medicare outpatient dialysis claims for the same patients. For each patient, the reported access from each data source was compiled; the percent agreement represented the percent of patients for whom the access was the same. Multivariate logistic analysis was performed to identify characteristics associated with the agreement of reported access.

Results

The two data sources agreed for 94% of patients, with a Kappa statistic of 0.83, indicating an excellent level of agreement. Further, we found no evidence to suggest that agreement was associated with the patient characteristics of age, sex, race, or primary cause of renal failure.

Conclusion

These results suggest that vascular access data as reported on form CMS-2728 are valid and reliable for use in research studies.

【 授权许可】

   
2014 Solid et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Barrett N, Spencer S, McIvor J, Brown EA: Subclavian stenosis: a major complication of subclavian dialysis catheters. Nephrol Dial Transplant 1988, 3:423-425.
• [2]Spinowitz BS, Galler M, Golden RA, Rascoff JH, Schechter L, Held B, Charytan C: Subclavian vein stenosis as a complication of subclavian catheterization for hemodialysis. Arch Intern Med 1987, 147:305-307.
• [3]National Kidney Foundation: An introduction to the kidneys and chronic kidney disease. Available at: http://www.kidney.org webcite. 2011. Accessed January 22, 2014
• [4]Astor BC, Eustace JA, Powe NR, Klag MJ, Fink NE, Coresh J: Type of vascular access and survival among incident hemodialysis patients: the choices for healthy outcomes in caring for ESRD (CHOICE) study. J Am Soc Nephrol 2005, 16:1449-1455.
• [5]Dhingra RK, Young EW, Hulbert-Shearon TE, Leavey SF, Port FK: Type of vascular access and mortality in U.S. hemodialysis patients. Kidney Int 2001, 60:1443-1451.
• [6]Feldman HI, Held PJ, Hutchinson JT, Stoiber E, Hartigan MF, Berlin JA: Hemodialysis vascular access morbidity in the United States. Kidney Int 1993, 43:1091-1096.
• [7]Gulati S, Sahu KM, Avula S, Sharma RK, Ayyagiri A, Pandey CM: Role of vascular access as a risk factor for infections in hemodialysis. Ren Fail 2003, 25:967-973.
• [8]Ishani A, Collins AJ, Herzog CA, Foley RN: Septicemia, access and cardiovascular disease in dialysis patients: the USRDS Wave 2 study. Kidney Int 2005, 68:311-318.
• [9]Nassar GM, Ayus JC: Infectious complications of the hemodialysis access. Kidney Int 2001, 60:1-13.
• [10]Perera GB, Mueller MP, Kubaska SM, Wilson SE, Lawrence PF, Fujitani RM: Superiority of autogenous arteriovenous hemodialysis access: maintenance of function with fewer secondary interventions. Ann Vasc Surg 2001, 18:66-73.
• [11]Polkinghorne KR, McDonald SP, Atkins RC, Kerr PG: Vascular access and all-cause mortality: a propensity score analysis. J Am Soc Nephrol 2004, 15:477-486.
• [12]Raithatha A, McKane W, Kendray D, Evans C: Catheter access for hemodialysis defines higher mortality in late-presenting dialysis patients. Ren Fail 2010, 32:1183-1188.
• [13]Schlieper G, Kruger T, Djuric Z, Damjanovic T, Markovic N, Schurgers LJ, Brandenburg VM, Westenfeld R, Dimkovic S, Ketteler M, Grootendorst DC, Dekker FW, Floege J, Dimkovic N: Vascular access calcification predicts mortality in hemodialysis patients. Kidney Int 2008, 74:1582-1587.
• [14]Woods JD, Port FK: The impact of vascular access for haemodialysis on patient morbidity and mortality. Nephrol Dial Transplant 1997, 12:657-659.
• [15]Xue JL, Dahl D, Ebben JP, Collins AJ: The association of initial hemodialysis access type with mortality outcomes in elderly Medicare ESRD patients. Am J Kidney Dis 2003, 42:1013-1019.
• [16]Chand DH, Teo BW, Fatica RA, Brier M: Influence of vascular access type on outcome measures in patients on maintenance hemodialysis. Nephron Clin Pract 2008, 108:c91-c98.
• [17]Goicoechea M, Caramelo C, Rodriguez P, Verde E, Gruss E, Albalate M, Ortiz A, Casado S, Valderrábano F: Role of type of vascular access in erythropoietin and intravenous iron requirements in haemodialysis. Nephrol Dial Transplant 2001, 16:2188-2193.
• [18]Lopez-Gomez JM, Portoles JM, Aljama P: Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality. Kidney Int 2008, 74(Suppl 111):S75-S81.
• [19]United States Renal Data System: The cost effectiveness of alternative types of vascular access and the economic cost of ESRD. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disorders; 1995:139-157.
• [20]Schon D, Blume SW, Niebauer K, Hollenbeak CS, de LG: Increasing the use of arteriovenous fistula in hemodialysis: economic benefits and economic barriers. Clin J Am Soc Nephrol 2007, 2:268-276.
• [21]Solid CA, Carlin C: Timing of arteriovenous fistula placement and Medicare costs during dialysis initiation. Am J Nephrol 2012, 35:498-508.
• [22]Wu LC, Lin MY, Hsieh CC, Chiu HC, Mau LW, Chiu YW, Chen HC, Hwang SJ: Planned creation of vascular access saves medical expenses for incident dialysis patients. Kaohsiung J Med Sci 2009, 25:521-529.
• [23]National Kidney Foundation. NKF K/DOQI Guidelines: Clinical practice guidelines and clinical practice recommendations, 2006 updates hemodialysis adequacy, peritoneal dialysis adequacy, vascular access. Available at: http://www.kidney.org/professionals/Kdoqi/guideline_upHD_PD_VA/va_guide1.htm webcite. Accessed January 22, 2014
• [24]Lok CE: Fistula first initiative: advantages and pitfalls. Clin J Am Soc Nephrol 2007, 2:1043-1053.
• [25]Lacson E Jr, Lazarus JM, Himmelfarb J, Ikizler TA, Hakim RM: Balancing fistula first with catheters last. Am J Kidney Dis 2007, 50:379-395.
• [26]US Renal Data System: USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease & End-Stage Renal Disease in the United States, Volume 2, Figure HP.13., 2010 ed. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2010:217.
• [27]Arce CM, Mitani AA, Goldstein BA, Winkelmayer WC: Hispanic ethnicity and vascular access use in patients initiating hemodialysis in the United States. Clin J Am Soc Nephrol 2012, 7:289-296.
• [28]Foley RN, Chen S, Collins A: Hemodialysis access at initiation in the US, 2005–2007: still “catheter first”. Hemodial Int 2009, 13:533-542.
• [29]Lilly MP, Lynch JR, Wish JB, Huff ED, Chen SC, Armistead NC, McClellan WM: Prevalence of arteriovenous fistulas in incident hemodialysis patients: correlation with patient factors that may be associated with maturation failure. Am J Kidney Dis 2012, 59:541-549.
• [30]McClellan WM, Wasse H, McClellan AC, Holt J, Krisher J, Waller LA: Geographic concentration of poverty and arteriovenous fistula use among ESRD patients. J Am Soc Nephrol 2010, 21:1776-1782.
• [31]Beaubrun AC, Kanda E, Bond TC, McClellan WM: Form CMS-2728 data versus erythropoietin claims data: implications for quality of care studies. Ren Fail 2013, 35:320-326.
• [32]Kim JP, Desai M, Chertow GM, Winkelmayer WC: Validation of reported predialysis nephrology care of older patients initiating dialysis. J Am Soc Nephrol 2012, 23:1078-1085.
• [33]Merkin SS, Cavanaugh K, Longenecker JC, Fink NE, Levey AS, Powe NR: Agreement of self-reported comorbid conditions with medical and physician reports varied by disease among end-stage renal disease patients. J Clin Epidemiol 2007, 60:634-642.
• [34]Cohen J: A coefficient of agreement for nominal scales. Educ Psychol Meas 1960, 20:37-46.
• [35]Fleiss JL, Cohen J: Large sample standard errors of kappa and weighted kappa. Psychological Bull 1969, 72:323-327.
• [36]Landis J, Koch G: The measurement of observer agreement for categorical data. Biogeosciences 1977, 33:159-174.